CC1(C)C(C)(C)OB([C:9]2[CH:14]=[CH:13][C:12]([C:15]([OH:18])([CH3:17])[CH3:16])=[CH:11][CH:10]=2)O1.Br[C:21]1[CH:26]=[CH:25][C:24]([C:27]2[N:32]=[C:31]3[N:33]=[C:34]([O:36][C@H:37]4[CH2:42][O:41][C@H:40]([CH2:43][OH:44])[C@@H:39]([OH:45])[CH2:38]4)[NH:35][C:30]3=[CH:29][C:28]=2[Cl:46])=[CH:23][CH:22]=1>O1CCOCC1.O.CCOC(C)=O.C1C=CC(P(C2C=CC=CC=2)[C-]2C=CC=C2)=CC=1.C1C=CC(P(C2C=CC=CC=2)[C-]2C=CC=C2)=CC=1.Cl[Pd]Cl.[Fe+2]>[Cl:46][C:28]1[CH:29]=[C:30]2[NH:35][C:34]([O:36][C@H:37]3[CH2:42][O:41][C@H:40]([CH2:43][OH:44])[C@@H:39]([OH:45])[CH2:38]3)=[N:33][C:31]2=[N:32][C:27]=1[C:24]1[CH:25]=[CH:26][C:21]([C:9]2[CH:10]=[CH:11][C:12]([C:15]([OH:18])([CH3:16])[CH3:17])=[CH:13][CH:14]=2)=[CH:22][CH:23]=12-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)propan-2-ol (50.4 mg, 0.192 mmol) and (2R,3 S,5R)-5-((5-(4-bromophenyl)-6-chloro-1H-imidazo[4,5-b]pyridin-2-yl)oxy)-2-(hydroxymethyl)-tetrahydro-2H-pyran-3-ol (70 mg, 0.154 mmol) were dissolved in dioxane (600 μl) and water (600 μl). The reaction mixture was sparged with N2 with 15 min and then [1,1′-Bis(Diphenylphosphino)-Ferrocene]Dichloropalladium (II) (22.53 mg, 0.031 mmol) was added. After stirring 3 h at 80° C., the reaction mixture was diluted with water and EtOAc. The aqueous phase was extracted with EtOAc (×2); and the combined extracts were washed with brine, dried over Na2SO4, filtered, and concentrated. The resulting residue was purified by mass directed reverse phase HPLC eluted with acetonitrile in water containing 0.1% formic acid. The desired fractions were combined and lyophilized to give the title compound as a white solid. LC-MS: calculated for C27H28ClN3O5 509.17 observed m/e: 509.87 (M+H)+ (Rt 1.12/2 min); 1H NMR δ (ppm) (CD3OD): 7.82 (s, 1H), 7.72 (s, 4H), 7.66 (d, 2H), 7.59 (d, 2H), 5.11 (septet, 1H), 4.34 (dd, 1H), 3.88 (dd, 1H), 3.66-3.59 (m, 2H), 3.37 (t, 1H), 3.18-3.15 (m, 1H), 2.76-2.74 (m, 1H), 1.68 (q, 1H), 1.58 (s, 6H).
Wird geladen…